Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Nurse-led care effectively reduces disease activity and improves self-efficacy in patients with rheumatoid arthritis, ...

OtulfiTM received a Health Canada Notice of Compliance (NOC) approval on December 30th for both subcutaneous and intravenous formulationsWith this approval, Fresenius Kabi Canada's immunology ...

Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for OtulfiTM, an ustekinumab biosimilar indicated for Crohn's disease, ulcerative colitis, plaque psoriasis ...

Regulatory ApprovalFormycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CESTThe issuer is solely ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

Patients with rheumatoid arthritis who demonstrate consistent long-term elevation of inflammatory markers have an increased ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

A study of biologic-naive patients with psoriasis or PsA found that IL-17, IL-12/23, and IL-23 inhibitors have comparable cardiovascular and thrombotic risk profiles as TNF inhibitors.

If you suffer from psoriasis, cooler weather could be bad news. Learn how high and low humidity levels can affect psoriasis ...

“I was an active child, and I loved sport. However, since getting diagnosed with ankylosing spondylitis, psoriatic arthritis ...